Abstract Objectives Rivaroxaban 2.5mg twice daily with aspirin 100mg daily was superior to aspirin 100mg daily in the COMPASS trial but the cost-effectiveness in Scandinavia is unknown. Design Mean lifetime costs (USDs) and quality-adjusted life-years were determined from a Scandinavian perspective using a 2-state Markov model with US mortality data. Subgroup and sensitivity analyses were performed.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lars Rydén
Preventing cardiovascular risk in people with prediabetes
FREE with registration! Log in or register to access the full article. References 1. Lindström, J ∙ Louheranta, A ∙ Mannelin, M ∙ et al., the Finnish Diabetes Prevention Study Group The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity Diabetes Care. 2003; 26:3230-3236 2. Ritsinger, V ∙ Tanoglidi, E ∙ Malmberg, K ∙ et al.
Linda Mellbin | Radcliffe Cardiology
Linda Mellbin is Associate Professor of Cardiology and Head of the Coronary Artery Disease Patient Area at Karolinska University Hospital in Stockholm, Sweden. Her research focus is on the field of diabetes and cardiovascular diseases at Karolinska Institutet.
SGLT2 inhibitors in clinical practice
SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These effects were consistent across a wide range of subgroups within these populations. This supports the eligibility of a large population with cardiorenal-metabolic diseases for treatment with SGLT2 inhibitors.
Diabetes och parodontit - viktig aspekt av diabetesvården
Typ 2-diabetes är en växande epidemi (från 151 miljoner år 2 000 till 537 miljoner år 2021), med en förväntad ökning till över en miljard år 2050 [1-5]. I dag har 10,5 procent av världens vuxna befolkningen diabetes, de flesta typ 2-diabetes. Till detta bör man lägga de 541 miljoner individer som har prediabetes. Cirka en tredjedel (240 miljoner) av de med typ 2-diabetes känner inte till sin sjukdom, det vill säga är omedvetna om riskerna och saknar därför skyddande råd och terapi.
The 1923 Nobel Prize for the discovery of insulin in a 100‐year perspective
Dear Editor, On December 10, 1923 the Nobel Prize was awarded according to the by-then tradition in the celebration hall of the Royal Musical Academy at Nybrokajen 11 in Stockholm, Sweden. But everything was not as usual at this time. The awardees of the prize in physiology or medicine Frederick G Banting and John J R Macleod from Toronto, Canada were unable to attend the ceremony, and their prize was received by the Ambassador of the British Commonwealth in Stockholm for further promotion.
Risk prediction in patients with diabetes: is SCORE 2D the perfect solution?
Save citation to file Format: Add to My Bibliography Your saved search Name of saved search: Search terms: Frequency: Which day? Which day? Report format: Send at most: Send even when there aren't any new results Optional text in email: Create a file for external citation management software
Is the impact of add on heart failure therapy influenced by background therapy?
Randomised clinical trials of novel pharmacological agents are essential to provide the highest level of evidence for medical treatments. Following careful evaluation, the results of such trials are incorporated into contemporary practice guidelines. The most recent guidelines on the management of heart failure were released by the European Society of Cardiology in 2021.
Heart failure at the crossroads of cardiology and diabetology
It is with great pleasure and pride that we, co-editors of this special issue in Diabetes Research and Clinical Practice, present a unique compilation of cutting-edge scientific papers addressing all aspects of the particularly complex clinical area caused by the interaction between heart failure (HF) and diabetes.
Towards living guidelines on cardiorenal outcomes in diabetes: A pilot project of the Taskforce of the Guideline Workshop 2020
Abstract In June 2020, the Taskforce of the Guideline Workshop 2019 convened via teleconferencing to initiate a pilot project that demonstrates the various processes and considerations involved in developing high-quality, evidence-based clinical practice guidelines for the medical management of individuals with type 2 diabetes (T2D) and its associated comorbidities, including cardiovascular disease (CVD) and chronic kidney disease (CKD).
The history of the Nobel Prize for the discovery of insulin
Abstract In 2021 we are celebrating the 100th anniversary of the discovery of insulin, which 1923 was awarded with a Nobel Prize in Physiology or Medicine to Banting and MacLeod. The development of insulin was foregone by an interesting piece of medical history starting with the first known mentioning of a disease resembling diabetes about 1550 BC in Eberś papyrus.
Sodium glucose transporter inhibition in heart failure From an unexpected side effect to a novel treatment possibility
Abstract Sodium-glucose transporter-2 inhibitors (SGLT2i), originally launched as glucose-lowering drugs, have been studied in large cardiovascular outcome trials to ascertain safety. Surprisingly, these compounds reduced the risk of cardiovascular events (cardiovascular death, non-fatal myocardial and non-fatal stroke) and total mortality.
Peripheral arterial disease and intermittent claudication in coronary heart disease patients
Highlights • Peripheral artery disease (PAD) is associated with an increased risk of fatal and non-fatal coronary heart disease (CHD). • In CHD patients without a previous diagnosis of PAD, intermittent claudication is not infrequent. • Diagnosed PAD is significantly associated with a worse CHD risk factor profile. • Patients with known PAD as well as those suspected of having PAD demonstrated a considerable loss of health-related quality of life.
Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries - Kornelia Kotseva, Guy De Backer, Dir
Appendix 1 EUROASPIRE V registry (EAV) Primary care EORP Oversight Committee Christopher P. Gale, GB (Chair); Branko Beleslin, RS; Andrzej Budaj, PL; Ovidiu Chioncel, RO; Nikolaos Dagres, DE; Nicolas Danchin, FR; David Erlinge, SE; Jonathan Emberson, GB; Michael Glikson, IL; Alastair Gray, GB; Meral Kayikcioglu, TR; Aldo P.
Proceedings of the Guideline Workshop 2019 - Strategies for the Optimization of Guideline Processes in Diabetes, Cardiovascular Diseases and Kidney Diseases
Abstract The Guideline Workshop 2019 was held on the initiative of the Forschergruppe Diabetes e.V (Diabetes Research Group). Discussion, as described in this manuscript, was conducted by all participants from the perspective of their respective medical associations.
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases
Introduction Patients with type 2 diabetes mellitus (T2DM) have a higher incidence of cardiovascular disease (CVD), with a still striking cardiovascular mortality despite continuous advances targeting multiple risk factors.1 Initial evidence from the UKPDS cohort clearly indicated that, at least in the absence of modern lipid-lowering and blood pressure-lowering drugs, an early and intensive glycaemic control lowers the incidence of late cardiovascular complications.2 However, successive...
Risk factor reduction in type 2 diabetes demands a multifactorial approach
Multifactorial management The principles for a target-driven multifactorial management of patients with diabetes and its pre-states are outlined in Figure 1 summarising the present treatment targets according to the 2019 European guidelines on diabetes, prediabetes and CVD.12 Figure 1. A summary of the most essential components and treatment targets of an evidence-based management of patients with diabetes and its pre-states (modified after reference12).
The metabolic syndrome – What is it and how should it be managed? - Peter M Nilsson, Jaakko Tuomilehto, Lars Rydén, 2019
Is there a common background for the components of the metabolic syndrome? In 2005, a joint statement of the American Diabetes Association and the European Association for the Study of Diabetes, ‘The metabolic syndrome: Time for a critical appraisal’,15 raised several questions regarding the syndrome.
Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications
Introduction Diabetes is a major cause of morbidity and mortality worldwide and it contributes substantially to healthcare costs.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry - Kornelia Kotseva, Guy De Backer, Dirk De Bacquer, Lars Rydén, Arno Hoes,
Article Information Article first published online: February 10, 2019; Issue published: May 1, 2019 Kornelia Kotseva1, 2, Guy De Backer1, 3, Dirk De Bacquer1, 3, Lars Rydén1, 4, Arno Hoes1, 5, Diederick Grobbee1, 6, Aldo Maggioni1, 7, Pedro Marques-Vidal1, 8, Catriona Jennings1, 2, Ana Abreu9, Carlos Aguiar1, 10, Jolita Badariene11, 12, Jan Bruthans1, 13, Almudena Castro Conde14, Renata Cifkova1, 13, Jim Crowley1, 15, Kairat Davletov16, Jaap Deckers1, 17, Delphine De Smedt1, 3, Johan De...
Corrections needed to 2016 ESC and AHA guidelines on heart failure
In 2016, the European Society of Cardiology (ESC) issued updated heart failure guidelines. These guidelines serve as authoritative advice for physicians, thereby improving cardiovascular care. Despite careful background work by the authors and reviewers who created these guidelines, some less well supported suggestions were included.
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text
8.?Management Management of patients with AF involves 3 objectives—rate control, prevention of thromboembolism, and correction of the rhythm disturbance, and these are not mutually exclusive. The initial management decision involves primarily a rate-control or rhythm-control strategy. Under the rate-control strategy, the ventricular rate is controlled with no commitment to restore or maintain sinus rhythm. The rhythm-control strategy attempts restoration and/or maintenance of sinus rhythm.
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
2hPG : 2-hour post-load plasma glucose ABI : ankle-brachial index ACCOMPLISH : Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension ACCORD : Action to Control Cardiovascular Risk in Diabetes ACE-I : angiotensin converting enzyme inhibitor ACS : acute coronary syndrome ACTIVE : Atrial fibrillation Clopidogrel Trial
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lars
Contact Lars, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack